Table 4.
Prescription rates for patients without or with comorbid psychiatric diagnosis between 2007 and 2017
| All patients (n = 772) | Without additional diagnosis (n = 321) | With additional diagnosis (n = 451) | χ2 (1, n = 772) | p | |
|---|---|---|---|---|---|
| Any medication | 94.4% (724) | 92.5% (297) | 94.7% (427) | 1.49 | 0.22 |
| Any psychotropics | 89.6% (692) | 86.0% (276) | 92.2% (416) | 7.91 | 0.005** |
| Antidepressant drugs | 71.2% (550) | 68.6% (220) | 73.2% (330) | 1.97 | 0.16 |
| SSRI | 30.6% (236) | 27.1% (87) | 33.0% (149) | 3.11 | 0.08 |
| SSNRI | 22.8% (176) | 22.1% (71) | 23.3% (105) | 0.14 | 0.70 |
| NaSSA | 15.0% (116) | 17.8% (57) | 13.1% (59) | 3.21 | 0.07 |
| TCA | 12.0% (93) | 9.3% (30) | 14.0% (63) | 3.78 | 0.05 |
| “Other antidepressants” | 13.9% (107) | 10.6% (34) | 16.2% (73) | 4.92 | 0.03* |
| Antipsychotic drugs | 62.0% (479) | 57.9% (186) | 65.0% (293) | 3.93 | 0.04* |
| SGA | 49.0% (378) | 46.7% (150) | 50.6% (228) | 1.10 | 0.30 |
| Low-potency FGA | 22.5% (174) | 20.2% (65) | 24.2% (109) | 1.65 | 0.20 |
| High-potency FGA | 4.4% (34) | 3.7% (12) | 4.9% (22) | 0.58 | 0.45 |
| Tranquilizing drugs | 28.1% (217) | 27.1% (87) | 28.8% (130) | 0.28 | 0.60 |
| Hypnotic drugs | 12.2% (94) | 10.9% (35) | 13.1% (59) | 0.83 | 0.36 |
| Antiepileptic drugs | 19.3% (149) | 16.2% (52) | 21.5% (97) | 3.39 | 0.07 |
| Lithium | 3.0% (23) | 1.2% (4) | 4.2% (19) | 5.71 | 0.02* |
SSRI selective serotonin reuptake inhibitor, SSNRI selective serotonin noradrenaline reuptake inhibitors, NaSSA noradrenergic and specific serotonergic antidepressants, TCA tricyclic antidepressants, SGA second-generation antipsychotics, FGA first-generation antipsychotics
*p < 0.05,**p < 0.01, reported p values are not corrected for multiple comparisons